Published in

Lippincott, Williams & Wilkins, Pharmacogenetics and Genomics, 12(21), p. 861-866, 2011

DOI: 10.1097/fpc.0b013e32834c6edb

Links

Tools

Export citation

Search in Google Scholar

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study.

Journal article published in 2011 by Laure Elens ORCID, Matthijs L. Becker, Vincent Haufroid, Albert Hofman, Loes E. Visser, Ron H. N. van Schaik, André G. Uitterlinden, Bruno Ch-H. Stricker, R. H. N. Van Schaik
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

CYP3A4 is involved in the oxidative metabolism of many drugs and xenobiotics including the HMG-CoA reductase inhibitor simvastatin. The objective of this study was to investigate whether a new CYP3A4 functional single nucleotide polymorphism (SNP) in intron 6 (CYP3A4*22) modifies the effect of simvastatin on total cholesterol (TOTc) or LDL cholesterol (LDLc) reduction in a population-based cohort study.